Quoin Pharmaceuticals to Announce Corporate Update and Fourth Quarter and Full-Year 2025 Financial Results on Thursday, March 26, 2026GlobeNewsWire • 03/19/26
Quoin Pharmaceuticals Announces FDA Grants Fast Track Designation for QRX003 for the Treatment of Netherton SyndromeGlobeNewsWire • 03/11/26
NETHERTON NOW Recognizes Rare Disease Day and Highlights Growing Global Awareness of Netherton SyndromeMCAP MediaWire • 02/26/26
Quoin Pharmaceuticals Announces Submission to Japanese MHLW for Orphan Drug Designation for QRX003 in Netherton SyndromeGlobeNewsWire • 01/27/26
Quoin Pharmaceuticals Files Breakthrough Medicine Designation Application in Saudi Arabia for QRX003 in Netherton SyndromeGlobeNewsWire • 01/20/26
Quoin Pharmaceuticals Announces Corporate Update and Third Quarter 2025 Financial ResultsGlobeNewsWire • 11/06/25
Quoin Pharmaceuticals to Provide Corporate Update and Announce Third Quarter 2025 Financial Results on Thursday, November 6, 2025GlobeNewsWire • 10/30/25
Quoin Pharmaceuticals Announces Private Placement Financing of Up to $104.5 MillionGlobeNewsWire • 10/10/25
Quoin Pharmaceuticals Releases Fifth NETHERTON NOW Video Featuring Writers and Influencers Allie and Kaleigh Fasanella, Twin Sisters Living with Netherton SyndromeGlobeNewsWire • 09/09/25
Quoin Pharmaceuticals Appoints New Chief Financial Officer to Support Commercialization StrategyGlobeNewsWire • 08/18/25
Quoin Pharmaceuticals Releases Fourth Episode in NETHERTON NOW Video Series Featuring International Patient Advocate Mandy Aldwin-EastonGlobeNewsWire • 08/12/25
Quoin Pharmaceuticals Announces European Medicines Agency (EMA) Grants Orphan Drug Designation for QRX003 for the Treatment of Netherton SyndromeGlobeNewsWire • 05/20/25
Quoin Pharmaceuticals Announces Initial Positive Clinical Data for QRX003 from Pediatric Peeling Skin Syndrome StudyGlobeNewsWire • 05/14/25
Quoin Pharmaceuticals Releases Second Episode of its “Living with Netherton” Series, as part of its ongoing NETHERTON NOW awareness campaignGlobeNewsWire • 04/10/25
Quoin Pharmaceuticals Announces Additional Positive ‘Whole Body' Clinical Data from Ongoing Pediatric Netherton Syndrome Study and Approval to Initiate Testing of a Second Pediatric PatientGlobeNewsWire • 04/02/25
Quoin Pharmaceuticals Files U.S. Patent Application for Novel Topical Formulations to Treat Netherton Syndrome and Other Skin DiseasesGlobeNewsWire • 03/25/25
Quoin Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full-Year 2024 Financial ResultsGlobeNewsWire • 03/13/25
Quoin Pharmaceuticals Files U.S. and International Patent Applications for Novel Topical Rapamycin Formulations to Treat Rare Disease IndicationsGlobeNewsWire • 03/04/25
Quoin Pharmaceuticals Announces Highly Positive ‘Whole Body' Clinical Data from Ongoing Pediatric Netherton Syndrome StudyGlobeNewsWire • 02/27/25
Quoin Pharmaceuticals Launches First Episode of “NETHERTON NOW” Video Series to Raise Awareness for Netherton SyndromeGlobeNewsWire • 02/25/25
Quoin Pharmaceuticals Launches ‘NETHERTON NOW' Campaign to Raise Awareness of Netherton Syndrome, a Rare Genetic Disease with No Approved Treatment or CureGlobeNewsWire • 02/04/25